Ore has assembled what we characterize as an “incubation” portfolio of pharmaceutical compounds. While we do not intend to spend public shareholder capital to fully develop these or any future compounds, in certain circumstances we are willing to make modest investments in small preclinical or clinical studies, formulation work, and/or intellectual property development in order to establish or substantially improve the attractiveness of our portfolio compounds to third-party funding sources.
Ore’s current portfolio includes four clinical-stage compounds, each of which has been successfully tested for safety in human subjects in at least one Phase I clinical study:
- ORE1001, a first-in-class, orally-administered small molecule drug for potential use in treating Inflammatory Bowel Disease (IBD) and other gastrointestinal indications. This compound was in-licensed from Millennium Pharmaceuticals after undergoing Phase I clinical testing. ORE1001 is the primary focus of our current “incubation” efforts.
- ORE10002, a small molecule serotonergic agent with potential utility in a number of inflammatory and autoimmune diseases. This compound was in-licensed from Lundbeck after being tested in Phase II clinical trials.
- ORE5002 (tiapamil), a small molecule L-type calcium channel antagonist with potential utility in a variety of diseases, including cardiovascular disease, various cognitive disorders, and certain gastrointestinal indications. This compound was in-licensed from Roche after advancing through Phase II clinical testing.
- ORE5007 (romazarit), a small molecule PPARα agonist with potential utility in certain autoimmune, metabolic, inflammatory, and gastrointestinal diseases. This compound was in-licensed from Roche after Phase II clinical testing.
All of our in-licensed pharmaceutical assets were identified through prior “Drug Repositioning” collaborations with major pharmaceutical companies. In these collaborations, we worked with our pharmaceutical partners to identify potential new clinical indications for compounds that had been de-prioritized but that appeared to have a favorable safety/tolerability profile based on prior clinical and preclinical testing. In total, Ore evaluated more than 100 clinical-stage compounds for eight leading pharmaceutical companies, including Pfizer, Roche, Abbott, and Eli Lilly.